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http://dx.doi.org/10.1016/j.cell.2013.10.029Many cancer patients suffer from metastatic relapse several years after they have undergone
radical surgery. Early cancer cell dissemination followed by a protracted period of dormancy poten-
tially explains this prevalent clinical behavior. Increasing evidence suggests that the metastasis-
initiating cells are cancer stem cells or revert to this functional state upon infiltrating a target organ.
Their entry into dormancy and subsequent reactivation are governed by intrinsic programs and by
contextual cues, which resemble those regulating the self-renewal capability of adult stem cells. In
addition, metastatic cells undergoing reactivation are nursed by specialized extracellular matrix
niches, which support positive signals, such as Wnt and Notch, and attenuate negative signals,
such as BMP. In spite of significant remaining uncertainties, these findings provide a framework
to understand the logic of metastatic dormancy and reactivation and open new avenues for thera-
peutic intervention.Introduction
Metastatic relapse almost invariably portends a poor prognosis,
asmetastatic outgrowths become rapidly recalcitrant to pharma-
cological treatment, seed additional metastatic colonies, and
eventually compromise the function of vital organs. Although the
clinical importance of metastasis has been obvious since the
recognition of cancer as adisease, the studyofmetastasis has re-
mained the domain of specialists until the end of the last century.
More recently, advances in genomics and mouse modeling have
fostered a renaissance of studies onmetastasis, leading to a con-
ceptual framework for the understanding of its biological basis
(Nguyen and Massague, 2007; Valastyan and Weinberg, 2011).
Metastasis is traditionally viewed as a linear series of discrete
events or steps, collectively referred to as the invasion-metas-
tasis cascade (Fidler, 2003) (Figure 1). The first step commences
when cancer cells at the primary site of tumor growth dissociate
from one another or from adjacent normal cells, induce partial
degradation of the underlying basement membrane, and pene-
trate into the underlying interstitial matrix (invasion). Subse-
quently, as part of the program that enables them to sculpt a
permissive microenvironment, tumor cells foster the develop-
mentof a tumor vasculature (neoangiogenesis), exploit itsdiscon-
tinuities to gain access to the bloodstream (intravasation), and
disseminate through the bloodstream (dissemination). Finally,
upon arresting in the microcirculatory system of the target organ
and infiltrating its stroma (extravasation), cancer cells adopt
various strategies to survive and eventually outgrow into macro-
scopic lesions (colonization). Systemic signals, which act directly
or indirectly on the microenvironment in which metastases arise
(systemic instigation and inhibition), influence this latter step
(Nguyen and Massague, 2007; Valastyan and Weinberg, 2011).750 Cell 155, November 7, 2013 ª2013 Elsevier Inc.The evolution of the cellular attributes that enable individual
tumor cells to successfully negotiate the invasion-metastasis
cascade is akin to a Darwinian selection process, whereby
only a small percentage of the cells that emerge from one step
acquire the genetic or epigenetic alterations that enable them
to complete the subsequent step (Fidler, 2003). Because signif-
icant attrition occurs at each step, the probability that individual
tumor cells traverse all of the steps of the invasion-metastasis
cascade is small. Yet, a discrete number of cancer cells
endeavor to accomplish this goal during the natural history of
the disease, as many patients eventually develop metastases
in multiple organs.
Recent studies have shed significant light on the molecular
mechanisms governing the invasion and dissemination phases
of metastasis (Kang and Pantel, 2013; Thiery et al., 2009). How-
ever, in spite of significant advances, the postdissemination
phase of metastasis has remained less well understood. Mathe-
matical modeling of clinical data and experiments in mouse
models suggest that cancer cells disseminating from prevalent
cancers, such as those of the breast and prostate, undergo an
extended period of proliferative dormancy at premetastatic sites
(Aguirre-Ghiso, 2007) (Figure 1). Situated between initial survival
and final outgrowth and seemingly a facultative step of coloniza-
tion, metastatic dormancy has remained relatively understudied.
In this Review, I will discuss the cellular participants and the
emerging molecular underpinnings of metastatic dormancy
and reactivation. Although significant uncertainties remain, a
flurry of recent studies has provided significant insight into the
mechanisms that enable disseminated cancer cells to survive
during dormancy and then outgrow into life-threatening lesions.
Understanding the logic behind these processes may lead to the
Figure 1. The Invasion-Metastasis Cascade
Genetic and epigenetic alterations endow cancer cells with the capabilities
that enable them to negotiate the sequential steps comprising the invasion-
metastasis cascade. A partial or complete EMT allows individual carcinoma
cells or small groups of carcinoma cells to disassociate from adjacent
epithelial cells and to invade into the underlying interstitial matrix (invasion). In a
tightly linked process, cancer cells co-opt a wide spectrum of host cells to
create a permissivemicroenvironment. Upon recruiting angiogenic endothelial
cells and inducing the development of a defective vasculature (angiogenesis),
cancer cells enter into the circulation (intravasation) and disseminate via the
bloodstream (blood-born dissemination). In a variation from the predominant
sequence depicted here, cancer cells enter into lymphatic vessels and colo-
nize loco-regional lymph nodes prior to entering into the blood stream. Upon
arresting in the microcirculation, cancer cells disrupt the endothelial junctions
and penetrate into the stroma of the target organ (extravasation). In the final
step, colonization, they resist apoptosis (initial survival), undergo a variable
period of dormancy (dormancy), and finally outgrow into macroscopic lesions
(outgrowth). In order to colonize a target organ, cancer cells need to mold a
permissive microenvironment. In certain cases, systemic signals retard the
vascularization of micrometastases (systemic inhibition), potentially explaining
why surgical resection of the primary tumor may induce rapid outgrowth of
metastatic lesions (Demicheli et al., 2007). Other systemic signals are pro-
posed to spur metastatic outgrowth via the recruitment of bone-marrow-
derived hematopoietic cells (systemic instigation).identification of novel therapeutic targets for the prevention or
treatment of metastatic disease.
Framework
The existence of a pause—or lag time—between dissemination
and metastatic outgrowth is not a new concept. Many patients
with carcinomas of the breast, prostate, and kidney or with mel-
anoma suffer from metastatic relapse several years after initial
diagnosis and radical surgery. Although most breast cancer
metastases are detected within 10 years of surgery, excessmor-
tality can be documented up to 20 years (Karrison et al., 1999).
Interestingly, most patients with HER2+ or triple-negative (TN)
breast cancers relapse early (<5 years from surgery), developinglung, brain, or liver metastases. In contrast, ER+ cancers exhibit
a relatively constant rate of relapse over several years and tend
to develop predominantly bone metastases (Kennecke et al.,
2010; Smid et al., 2008). Late relapses thus appear to be a func-
tion of molecular subtype and to result from a specific dissemi-
nation pathway, at least in breast cancer. In prostate cancer,
the median time from PSA-only recurrence after radical prosta-
tectomy to bone metastasis and death exceeds 16 years (Freed-
land and Moul, 2007). Ultra-late recurrences (after 10–15 years)
are also frequent in melanoma and renal cell carcinoma, where
they affect multiple organ sites, excluding the hypothesis that
the bone is a privileged site for late relapse in these cancers
(McNichols et al., 1981; Tsao et al., 1997).
Mathematical modeling suggests that late relapses are incon-
sistent with a continuous growth model, whereby cancer cells
start to outgrow as soon as they infiltrate a target organ. In
fact, retrospective analysis of >1,000 breast cancer patients
has indicated that premenopausal women experience two
distinct peaks of metastatic risk, one at about 10 months and
the other at about 30 months after surgery (Demicheli et al.,
2007). Whereas the first peak is compatible with the continuous
growth model, the second peak suggests an interposed period
of dormancy. Additional clinical evidence for a lag time comes
from the rare but well documented transmission of melanoma
and choriocarcinoma by kidney transplantation (Strauss and
Thomas, 2010). In these cases, the donors had passed pre-
transplantation screening because they were cancer free for
more than 10 years; however, their kidneys must have harbored
dormant cancer cells, which underwent reactivation in the immu-
nosuppressed host. Melanomas and choriocarcinomas exhibit a
high rate of transmission during transplantation of various organs
(Buell et al., 2004). Biological characteristics, such as the pres-
ence of a high proportion of tumor-initiating cells in melanomas
(Quintana et al., 2008) and of embryonic carcinoma cells in
choriocarcinomas (Gokhale and Andrews, 2012), may explain
this behavior.
In parallel, studies in mouse models and clinical studies have
provided evidence that tumor cells can disseminate early during
the natural history of the disease. Although they are classified as
noninvasive, the mammary intraepithelial neoplasia (MIN) le-
sions, which arise in MMTV-Neu andMMTV-PyMTmice, release
potentially metastatic tumor cells in the circulation. In fact, 80
disseminated tumor cells are sufficient to induce a rapidly lethal
carcinosis when they are activated by bone marrow transplanta-
tion into wild-type recipient mice (Hu¨semann et al., 2008). In
agreement with these observations, clinical studies have identi-
fied disseminated cancer cells in the bone marrow of patients
with early-stage breast cancer (Pantel et al., 2008). In addition,
lineage-tracing experiments in a mouse model of pancreatic
cancer have indicated that tumor cells that have undergone an
EMT and acquired stem cell traits can delaminate from preinva-
sive pancreatic intraepithelial neoplasia (PanIN) lesions, enter
into the circulation, and seed the liver. In fact, in this model
even premalignant pancreatic cells can undergo an EMT in
response to inflammation and disseminate to the liver (Rhim
et al., 2012). Similarly, morphologically normal mammary epithe-
lial cells that have been explanted from donor mice and injected
in the tail vein of recipient mice infiltrate the lung and, uponCell 155, November 7, 2013 ª2013 Elsevier Inc. 751
Figure 2. Relationship between Early Dissemination, Metastatic
Dormancy, and Reactivation
(A) Although carcinomas in situ can release potentially metastatic cells in the
bloodstream, the number and metastatic capacity of cancer cells deposited at
premetastatic sites presumably increases as primary tumors progress toward
increasing malignancy. Experiments performed by inoculating B16F1 mela-
noma cells directly in the circulation of mice suggest that the efficiency of
extravasation is 20% and that that of initial survival is 4% (Luzzi et al.,
1998).
(B) A large fraction of cancer cells, which have remained viable in the target
organ, enters into solitary dormancy before surgical resection of the primary
tumor interrupts dissemination. After a variable lag time, a small minority of
dormant cells undergoes reactivation and gives rise to metastatic outgrowths.
Experiments performed by inoculating B16F1 melanoma cells directly in the
circulation of mice suggest that a large fraction of micrometastases regress
because they fail to establish a permissive microenvironment, further
contributing to the inefficiency of colonization (Luzzi et al., 1998). However, a
small fraction of micrometastases spawns macroscopic lesions. It is debated
whether micrometastatic dormancy occurs and, if so, whether it interrupts
secondary tumor growth for a significant period of time. The cancer cells that
comprise a macrometastasis have solved the adaptation problem and can
therefore seed additional macrometastases in the same organ. Percentages of
attrition are derived from the analysis of a single xenograft model and are
therefore intended for illustrative purpose.oncogene induction, give rise to macroscopic metastases (Pod-
sypanina et al., 2008). Early dissemination potentially explains
the appearance of metastatic lesions in patients who have un-752 Cell 155, November 7, 2013 ª2013 Elsevier Inc.dergone surgical removal of small, seemingly noninvasive
tumors several years earlier (Pantel et al., 2008) or in patients
with no detectable primary tumor (metastasis of unknown pri-
mary tumor; 4%–5% of all metastases) (Greco and Hainsworth,
2009).
Although the metastatic capacity of tumor cells disseminating
from MIN and PanIN lesions is, in the above studies, induced by
experimental manipulation or inferred from their phenotype, it
seems plausible that at least some of the tumor cells dissemi-
nating from these early lesions have metastatic capacity. In
fact, the tumor cells found in the bone marrow aspirates of
patients with cancers of the breast, prostate, lung, and colon
are growth arrested, yet their abundance directly correlates
with reduced metastasis-free survival, suggesting that some of
these cells eventually exit fromproliferative quiescence to initiate
metastatic growth (Pantel et al., 2008). Taken together, these
findings suggest that early dissemination and a protracted
period of metastatic dormancy characterize the natural history
of many prevalent cancer types.
The dormancy reactivation model is not inconsistent with the
well-established correlation between primary tumor size and
poor prognosis observed in the clinic because, as primary tu-
mors expand, they generate and release into the bloodstream
larger numbers of metastatic tumor cells (Figure 2A). In fact,
even cancers characterized by a very rapid clinical progression,
such as those of the pancreas, may follow thismodel, asmuch of
their genetic evolution occurs in the decade preceding clinical
detection (Yachida et al., 2010). However, in spite of the appeal
of the dormancy reactivation model, its essential tenet—that
early dissemination produces dormant cells, which at a later
stage spawn metastatic deposits—remains to be formally
demonstrated.
Primary Tumor Dormancy and Metastatic Dormancy
Broadly defined, tumor dormancy represents a lag in tumor
growth, which may occur during the formation of primary tumors
or after the dissemination of some of their constituent cells. How-
ever, primary tumor dormancy and metastatic dormancy appear
to be distinct processes (Weinberg, 2008). Primary tumors may
undergo a phase of dormancy during neoplastic conversion as
incipient neoplastic cells acquire the additional somatic muta-
tions required to bypass oncogene-induced apoptosis or senes-
cence (Lowe et al., 2004) and, at a later stage, as neoplastic cells
evolve the ability to evade immune recognition (Quezada et al.,
2011) and to elicit neoangiogenesis (Chung and Ferrara, 2011).
In contrast, tumor cells deposited at premetastatic sites seem
to undergo dormancy as a result of delayed adaption to the
foreign microenvironments in which they find themselves.
In spite of its clinical importance, metastatic dormancy has
remained relatively understudied, in large part because of the
scarcity of mouse models that recapitulate the complexity of
this process. Dissemination and metastatic seeding occur in
an asynchronous manner in genetically engineered mouse
models and in patients, limiting kinetic analysis. Therefore,
insights into the nature of metastatic dormancy and reactivation
have largely been obtained from xenograft models. Early studies
showed thatmost of the intravenously inoculated B16melanoma
cells, which had successfully infiltrated the liver or lung
parenchyma and survived initial attrition, entered into a pro-
tracted state of proliferative quiescence (Cameron et al., 2000;
Luzzi et al., 1998). A small minority of tumor cells underwent
limited expansion to give rise to micrometastatic lesions, and
an even smaller fraction of these micrometastases eventually
outgrew into macroscopic lesions, setting the stage for the defi-
nition of solitary tumor cell dormancy and micrometastatic
dormancy (Cameron et al., 2000; Luzzi et al., 1998) (Figure 2B).
Potentially arranged as subsequent periods of interrupted tumor
growth, solitary tumor cell dormancy and micrometastatic
dormancy seem to originate from fundamentally distinct mecha-
nisms. Solitary tumor cells do not outgrow because they possess
tumor cell-intrinsic defects or because they find themselves in
inhospitable microenvironments. In contrast, micrometastatic
lesions do not expand in size because their constituent cells
undergo cell division and apoptosis at similar rates. They appear
to have solved the initial adaptation problem only to encounter
another barrier to further expansion.
Analysis of additional tumormodels has revealedmechanisms
potentially involved in limiting the expansion of micrometastasis.
Resection of subcutaneous Lewis lung carcinomas induces
angiogenic switch and hence explosive outgrowth of lung micro-
metastases, suggesting that systemic signals originating from
the primary tumor limit the neovascularization of micrometasta-
sis, holding them in check (Holmgren et al., 1995). Furthermore,
studies on melanoma, lymphoma, and prostate adenocarci-
noma models suggest that immunosurveillance mechanisms
may also contribute to halt the expansion of micrometastases
(Eyles et al., 2010; Rabinovsky et al., 2007). These observations
suggest that tumor cells that have extravasated in a target organ
remain dormant for extended periods as a consequence of their
inability to exit from proliferative quiescence (solitary tumor cell
dormancy) or that they give rise to micrometastatic lesions that
are unable to outgrow until they avert immunosurveillance
and elicit a supportive angiogenic response (micrometastatic
dormancy) (Aguirre-Ghiso, 2007).
Arguably, disseminated tumor cells originate from primary
tumors that have evaded immune recognition and have under-
gone an angiogenic switch. Why would these tumor cells
need to evolve new capacities to exit from micrometastatic
dormancy? The observation that pathological lesions put their
signature on the vasculature, leading to the generation of
vascular zip codes, suggests that partially distinct mechanisms
govern neoangiogenesis within primary tumors and atmetastatic
sites (Ruoslahti, 2002), necessitating the acquisition of new
capabilities by metastatic cells. Similarly, the interaction of
metastatic tumor cells with their newfound home may evoke
novel innate and adaptive immune responses, which would
need to be overcome for reactivation. However, because many
tumor cells within micrometastases undergo active proliferation,
they can readily acquire heritable attributes, which increase their
fitness, in agreement with the hypothesis that micrometastatic
dormancy constitutes a temporary barrier to successful coloni-
zation (Taylor et al., 2013) (Figure 2B).
Hormone-dependent cancers, such as adenocarcinomas of
the prostate and ER+ breast cancers, may undergo dormancy
in response to hormonal therapy. Studies in subcutaneous
models of breast cancer dormancy suggest that hormone depri-vation therapy induces these tumors to regress to small masses,
wherein proliferation is balanced by apoptosis (Noble, 1977;
Wijsman et al., 1991). This suggests that the ER antagonists
that are commonly used as adjuvant therapy in ER+ breast
cancers may exert their effect by preventing the outgrowth of
micrometastases. AR antagonists may exert a similar effect in
prostate cancer. Although potentially important, endocrine
dormancy remains relatively understudied.
Experiments on a mouse model of breast cancer dormancy in
the liver have revealed an important feature of dormant tumor
cells: consistent with their permanence in the G0 phase of the
cell division cycle, these cells are refractory to conventional
chemotherapy (Naumov et al., 2002, 2003). Micrometastases,
such as those detected in the lymph nodes of breast cancer
patients, contain a small proportion of cycling tumor cells and
may be similarly resistant to anti-mitotic therapies (Klauber-
DeMore et al., 2001). These results suggest that both solitary
tumor cells and micrometastatic lesions are resistant to adjuvant
chemotherapy. This model implies that adjuvant chemotherapy
can only eradicate the solitary tumor cells or micrometastases
that stochastically exit from dormancy during the treatment
period.
Toward a Definition of Metastatic Cancer Stem Cells
Three types of tumor heterogeneity bear significance to the
understanding of metastatic dormancy and reactivation. First,
increasing evidence suggests that many carcinomas exhibit a
hierarchical organization, wherein only cancer stem cells have
tumor-initiating capacity, whereas the remaining rapidly prolifer-
ating or aberrantly differentiated tumor cells lack this property
(Reya et al., 2001). Cancer stem cells may arise from oncogenic
transformation of adult stem cells or from transient-amplifying
cells and do not necessarily phenocopy all of the behaviors
exhibited by embryonic or adult stem cells, as they are not
patently multipotent and they divide predominantly symmetri-
cally (Clevers, 2011; Gupta et al., 2009). Second, most carci-
nomas undergo clonal evolution as their constituent cells acquire
heritable traits that foster tumor progression and metastasis
(Baylin and Jones, 2011; Fidler and Hart, 1982; Nowell, 1976).
Although it is plausible that the genetic and epigenetic modifica-
tions that sustain these traits arise in cancer stem cells, it is also
possible that they occur in progenitors devoid of substantial self-
renewal capability and that subsequent alterations induce these
progressed progenitors to acquire tumor-initiation capacity.
Finally, tumor cells recruit a complex array of stromal elements,
including activated fibroblasts and immune and vascular cells,
which foster tumor progression through paracrine mechanisms
(Joyce and Pollard, 2009). In some cases, cells of the tumor
microenvironment produce cytokines, such as Wnt proteins,
secreted inhibitors of BMP, and delta, which activate signaling
pathways that sustain the self-renewal capacity of cancer stem
cells (Reya et al., 2001). In others, they initiate inflammatory
signals that induce transient-amplifying cells to dedifferentiate
to cancer stem cells, pointing to the existence of a significant de-
gree of plasticity (Schwitalla et al., 2013).
Increasing evidence indicates that the tumor cells that initiate
metastatic outgrowth are cancer stem cells or, at least, possess
several attributes of these cells. During tumor progression,Cell 155, November 7, 2013 ª2013 Elsevier Inc. 753
cancer cells often hijack the developmental program of epithe-
lial-to-mesenchymal transition (EMT), shedding their epithelial
attributes, such as robust cadherin-dependent junctions, and
gaining invasive ability (Thiery et al., 2009). In support of the
importance of this program, expression of the EMT-inducing
transcription factors Twist and Snail promotes dissemination
and metastasis of mammary carcinoma in mice (Yang et al.,
2004; Moody et al., 2005). In addition, the proportion of circu-
lating tumor cells exhibiting mesenchymal features increases in
advanced-stage breast cancer (Yu et al., 2013). Intriguingly,
ectopic expression of Twist or Snail confers mesenchymal as
well as stem cell properties upon normal mammary epithelial
cells, and it induces enhanced tumor initiation and metastatic
capacity in their transformed derivatives (Mani et al., 2008;
Scheel et al., 2011). Zeb1 exerts a similar effect by repressing
the ability of miR-200 family members to inhibit stemness and
to induce epithelial differentiation (Korpal et al., 2011; Shimono
et al., 2009; Wellner et al., 2009). Conversely, re-expression
of the luminal cell fate determinant GATA3 causes tumor cell
differentiation and blocks dissemination and metastasis in the
MMTV-PyMT mouse model of mammary tumorigenesis (Asse-
lin-Labat et al., 2011; Kouros-Mehr et al., 2008). These studies
suggest that dedifferentiation or passage through an EMT and
the attendant acquisition of stem cell properties facilitate
dissemination and metastasis.
Some of the contextual signals originating from the tumor
microenvironment, such as TGF-b, can induce tumor cells to
pass throughanEMTandacquirecancer stemcell activity (Scheel
et al., 2011). This suggests that, even when a primary tumor ex-
hibits a well-differentiated histological appearance, some of its
constituent cellsmayacquire stemcell traits in response tomicro-
environmental cues (Polyak and Weinberg, 2009). However,
becausecommononcogenicmutations, suchas theamplification
of HER2, promote disruption of epithelial adhesion and polarity
and invasion without inducing a full EMT, dissemination may not
necessarily require sheddingof epithelial attributes (Muthuswamy
andXue, 2012).Moreover, the observation thatmetastatic lesions
originating from human carcinomas almost invariably display
epithelial features, such as well-organized adherens junctions,
suggests that tumor cells that have disseminated through an
EMT revert to an epithelial phenotype through a mesenchymal-
to-epithelial transition (MET) as they outgrow into macroscopic
metastases (Chaffer and Weinberg, 2011).
Prospective identification studies have lent additional support
to the model that only the subpopulation of tumor cells that
exhibits cancer stem cell features possesses the capacity to
generate metastasis. In human pancreatic carcinomas, this ca-
pacity is restricted to a subpopulation of CD133+ CXCR4+
tumor-initiating cells, which are found at the invasive edges of
primary tumors (Hermann et al., 2007). In human colorectal can-
cers, the abundance of CD26+ tumor-initiating cells correlates
with the development of liver metastases. When the CD26+ cells
are injected in the cecal wall of mice, they produce liver metas-
tases, whereas the remaining tumor cells lack this capacity
(Pang et al., 2010). In the same cancers, molecular marking of
tumor-initiating cells reveals that only those endowed with the
highest self-renewal capacity can metastasize (Dieter et al.,
2011). Finally, expression of an embryonic stem cell transcrip-754 Cell 155, November 7, 2013 ª2013 Elsevier Inc.tional program identifies poor prognosis patients in several can-
cer types (Ben-Porath et al., 2008; Wong et al., 2008). These
studies suggest that the cancer stem cells can initiate the forma-
tion ofmetastases, whereas the remaining tumor cells are devoid
of this capacity, reinforcing the link between stem cell activity
and metastasis. However, it remains unclear whether metastatic
colonization is initiated by the same pool of cancer stem cells
that sustains primary tumor growth or by some descendants of
these cells, which retain self-renewal and tumor-initiation capac-
ity or reacquire it upon migrating into target organs.
Tumor Evolution and Dormancy
Although it iswidely accepted that clonal evolution underlies pas-
sage through the invasion-metastasis cascade, there remains a
considerable degree of uncertainty regarding the rate at which
subclones carrying beneficial new mutations are generated and
lost; the physical location where progressor subclones arise
(i.e., in primary tumors or after dissemination); and even the uni-
directionality of the invasion-metastasis cascade. In particular,
because colonization is rate limiting for metastasis and involves
the acquisition of heritable traits that favor outgrowth in the target
organ, but not necessarily at the primary site, it remains unclear
how, when, andwhere tumor cells acquire these traits (Valastyan
andWeinberg, 2011). These uncertainties limit our current under-
standing of the postdissemination phase of metastasis and
thereby of metastatic dormancy and reactivation.
In somecases, it is possible that thecell of origin of a tumormay
already possess the capacity to survive and proliferate in a spe-
cific foreignmicroenvironment; therefore, its transformed deriva-
tives will be able to outgrow in that organ once they have
successfully negotiated the preceding steps of the invasion-
metastasis cascade. In many cases, however, it is plausible
that neoplastic cells acquire the genetic and epigenetic changes
that support colonization while they are still at the primary site.
Because these changes presumably originate from mutational
events, which do not confer a strong competitive advantage at
the primary site, they may not be prevalent within the primary
tumor. Indeed, recent genomic studies on patient-matched
primary tumors and metastases of breast cancer and medullo-
blastoma and on different geographical regions of the same
primary renal cell carcinoma and its metastatic derivatives
support the view that metastases originate from a rare subclone
within primary tumors (Ding et al., 2010;Gerlinger et al., 2012;Wu
et al., 2012). In addition, it is likely that some of these changes
occur after dissemination, imparting increased proliferative abil-
ity upon a tumor cell that is already able to survive within the
stroma of a foreign organ. Recent genomic studies are also
consistent with this view, as they have documented additional
drivermutations and have even provided evidence of convergent
evolution in themetastatic clonesof pancreatic and renal cancers
(Campbell et al., 2010;Gerlinger et al., 2012;Yachidaet al., 2010).
In an extreme view, the quasi-normal cells that are released
from premalignant lesions acquire all of the genetic changes
necessary for colonization after they have disseminated and
entered into dormancy (Klein, 2009). Although this model
appears to be supported by an examination of the copy-number
alterations present in single disseminated breast cancer cells
(Schardt et al., 2005; Schmidt-Kittler et al., 2003), the methods
Figure 3. Survival and Stress Signaling in
Metastatic Dormancy and Reactivation
(Top) Adhesive and signaling interactions leading
to activation of AKT support the survival of cancer
cells during dormancy and reactivation. (Bottom)
Stress signals initiated by p38 kinase and leading
to the activation of the unfolded protein response
(UPR) and of TOR contribute to dormancy,
whereas activation of ERK may contribute to re-
activation (bottom).used to isolate these cells did not necessarily capture metas-
tasis-initiating cells, as they relied on the expression of epithelial
differentiation markers, such as EpCAM and cytokeratins. More-
over, it is difficult to envision how quasi-normal cells that have
disseminated in a target organ could acquire the multiple alter-
ations that are presumably necessary for colonization in the
absence of rapid proliferation. One possibility, supported by
studies in mouse models as well as by certain clinical observa-
tions, is that tumor cells that have acquired metastatic ability
and have disseminated to a target organ repopulate the primary
tumor from which they originated (Norton and Massague´, 2006).
This model readily explains how primary tumors can acquire
many of the genetic determinants of metastatic clones. How-
ever, it does not explicitly inform us about the mechanisms
that would allow disseminated tumor cells to acquire the compe-
tence for colonization after removal of the primary tumor.
Irrespective of which specific model may better explain the
evolution of cancer, it is likely that the percentage of circulating
tumor cells partially competent for colonization increases as
primary tumors progress toward increasing malignancy. If the
primary tumor is not detected and resected very early, these
cells may find themselves in foreign environments that are not
conducive to their reactivation and, hence, enter into dormancy
(Figure 2). If this is indeed the case, how do metastasis-initiating
cells evolve the attributes that are required for full adaptation and
reactivation while remaining quiescent at premetastatic sites?
Because genetic changes are less likely to occur and to be
selected for in the absence of overt proliferation, even in genet-
ically unstable tumor cells (Michor et al., 2004), it is plausible that
adaptation and reactivation are driven by nongenetic mecha-
nisms, such as bidirectional interactions with the tumor microen-
vironment, changes in metastable configurations of signaling
networks, or altered epigenetic states. In support of this hypoth-
esis, lentiviral lineage tracking has revealed the existence of twoCell 155,types of genetically indistinguishable
tumor-initiating cells in colorectal cancer.
Although some of these putative cancer
stem cells oscillate between slow and
rapid proliferation, others are predomi-
nantly dormant. Intriguingly, chemo-
therapy eliminates the first type of cells,
but it induces reactivation of the dormant
ones (Kreso et al., 2013). In addition, it
has been noted that microenvironmental
signals, such as TGF-b, can induce plas-
tic basal-like CD44lo breast cancer cells
to acquire cancer stem cell traits via chro-matin remodeling at the ZEB1 promoter (Chaffer et al., 2013).
This raises the possibility that noncancer stem cells may infiltrate
target organs and remain dormant until contextual signals
induce their conversion to cancer stem cells and reactivation.
Alternatively, it is possible that the metastasis-initiating cells
do not remain stationary at premetastatic sites but recirculate
between tissue microenvironments, including sanctuaries such
as the bone marrow, where they would find conditions that are
appropriate for limited expansion and chance acquisition of the
traits required for their rapid reactivation in the final target organ
(Meads et al., 2008). In agreement with this hypothesis, a size-
able fraction of disseminated tumor cells that are present in the
bone marrow of patients affected by colorectal carcinoma and
ER+ breast cancer is actively proliferating, even though the
bone is infrequently the first site of metastatic relapse in these
tumor types (Schindlbeck et al., 2005; Schlimok et al., 1990).
The Dormant State
Several studies support the notion that disseminated tumor cells
undergo proliferative arrest upon infiltrating a target organ
because they find themselves deprived of appropriate adhesive
and signaling interactions (Liu et al., 2002; Shibue et al., 2012;
Shibue and Weinberg, 2009). This suggests that dormancy is
induced by maladaptation and must be resolved by genetic or
epigenetic alterations that increase the fitness of dormant cells
within a specific tissue microenvironment. In agreement with
this notion, enhanced survival signaling appears to be a prereq-
uisite for dormancy (Figure 3, top). Analysis of a large cohort of
breast cancer patients has indicated that expression of a Src
signature correlates with late relapse to the bone, but not to other
organs. Subsequent mechanistic studies have revealed that Src
supports the survival of indolent breast cancer cells in the bone
marrow by activating Akt in response to the engagement of the
CXCR4 receptor by SDF1 (Zhang et al., 2009). Similarly, breastNovember 7, 2013 ª2013 Elsevier Inc. 755
Figure 4. Stem Cell Signaling Pathways and
Transcriptional Circuits Implicated in Meta-
static Reactivation
The stem cell signaling pathways and transcrip-
tional circuits that are implicated in metastatic
colonization or, specifically, reactivation are illus-
trated diagrammatically. The interactions between
signaling components, transcription factors, and
functional outputs are largely inferred from studies
on embryonic and adult stem cells (Clevers and
Nusse, 2012; Guruharsha et al., 2012; Wakefield
and Hill, 2013; Young, 2011). Signaling pathways,
such as Wnt/b-catenin and Notch, promote cell-
cycle progression viaMyc andCyclin D1.Myc also
induces expression of the polycomb repressor
complex 1 component Bmi-1. Together with JAK/
STAT3, these pathways induce expression of
SOX2, OCT4, and NANOG, which constitute the
core transcriptional circuit regulating self-renewal.
BMP signaling opposes the upregulation of these
core factors. Additional transcription factors
determine progenitor identity and/or induce an
EMT. PRRX1 also controls expression of SOX9
(Reichert et al., 2013). Broken lines denote indirect
signaling interactions. Solid lines illustrate direct
transcriptional interactions. (Rectangles) tran-
scription factors; (ovals) cell-cycle components;
(octagon) epigenetic regulator. Functional groups
are color coded.cancer cells expressing VCAM1 thrive in the lung because
engagement of VCAM1 by stromal macrophages expressing
a4 integrins triggers activation of Akt (Chen et al., 2011). These
studies suggest that enhanced Akt signaling supports the sur-
vival of breast cancer cells entering into both lung and bone.
Stress signals mediated by the p38MAPKmay also contribute
to enhance the fitness of tumor cells during dormancy (Figure 3,
bottom). In fact, analysis of a chicken choioallantoic membrane
(CAM) model of dormancy has revealed that squamous carci-
noma cells enter into proliferative quiescence as a result of a
higher ratio of flux through the p38 over the ERK-signaling
pathway (Aguirre-Ghiso et al., 2003; Aguirre-Ghiso et al.,
2001). Elevated p38 kinase activity induces activation of the
unfolded protein response (UPR), which upregulates the ER
stress-regulated transcription factor ATF6. ATF6 in turn pro-
motes survival of dormant cells through upregulation of Rheb
and thereby mTOR signaling (Ranganathan et al., 2006; Schewe
and Aguirre-Ghiso, 2008). In addition, analysis of a subcutane-
ous xenograft model of tumor dormancy has suggested the hy-
pothesis that the Ras-related tumor suppressor ARHI promotes
the survival of ovarian carcinoma cells by inducing autophagy
(Lu et al., 2008). These findings suggest that dormant tumor cells
exploit paracrine interactions with elements of the tumor micro-
environment as well as endogenous stress signaling to activate a
variety of protective responses that enhance their survival.
Even if they are fully adapted to their newfound home, the
metastasis-initiating cells may exit the cell cycle in response to
contextual signals and endogenous programs that are similar
to those that suppress the self-renewal capability of adult stem
cells. In a mouse model of metastatic dormancy, mammary car-
cinoma cells that have successfully extravasated in the lung and
have survived initial attrition remain dormant for an extended
period of time because stroma-derived BMP proteins limit their756 Cell 155, November 7, 2013 ª2013 Elsevier Inc.ability to outgrow. Treatment with BMP or genetic activation of
BMP signaling inhibits the ability of breast cancer cells to mani-
fest cancer stem cell traits in vitro and to initiate tumorigenesis
upon transplantation in vivo (Gao et al., 2012b). Prostate cancer
cells may also be sensitive to the inhibitory action of BMP
because systemic treatment with BMP blocks the outgrowth of
intratibially injected prostate carcinoma cells (Kobayashi et al.,
2011). These findings suggest that paracrine BMP signaling
induces metastasis-initiating cells to enter into dormancy by in-
hibiting their capacity for self-renewal. This model is consistent
with previous studies indicating that activation of the BMP
pathway inhibits self-renewal and promotes differentiation in
pluripotent embryonic stem cells and adult stem cells from
various tissues, including those of the central nervous system
subventricular zone, intestinal epithelium, and hair follicle bulge
(Wakefield and Hill, 2013). In addition, deactivation of oncogenic
Myc, which promotes self-renewal, induces hepatocellular car-
cinoma cells to exit from the cell cycle and differentiate enmasse
into hepatocytes and biliary cells, suggesting that a reduction in
the expression of an endogenous positive regulator of self-
renewal may induce dormancy as a byproduct of aberrant differ-
entiation (Shachaf et al., 2004). These findings suggest that
disseminated tumor cells can undergo dormancy as a conse-
quence of intrinsic defects or in response to inhibitory signals
originating in the parenchyma of target organs.
Stem Cell Transcriptional Networks in Metastatic
Colonization
Several studies have implicated stem cell signaling pathways
and the transcriptional networks that they govern in metastatic
colonization of target organs, although not specifically in reacti-
vation from the dormant state (Figure 4). Human lung adenocar-
cinomas, which possess elevated Wnt/b-catenin signaling and
Figure 5. Metastatic Niches
Coco is retained at the cell surface presumably because it binds to cell surface
proteoglycans. It thereby effectively shields outgrowing cancer cells from the
inhibitory action of BMP proteins produced by host cells. Fibronectin fibrils
that are decorated by tenascin-C and periostin nurse outgrowing micro-
metastases by promoting activation of the Notch- and b-catenin/TCF-
signaling pathways. Tenascin-C can engage integrins as well as Syndecan 4.
The latter can function as a coreceptor for Frizzled. Periostin facilitates pre-
sentation of Wnt to Frizzled and also binds to integrins. Tenascin-C promotes
activation of Notch- and b-catenin/TCF-signaling via Musashi-1 and Lgr5,
respectively (Oskarsson et al., 2011).hence express a WNT/TCF-dependent transcriptional program,
progress rapidly to metastasis. Inhibition of TCF-dependent
gene expression does not affect primary tumor growth but
suppresses colonization of the bones and brain, suggesting a
specific involvement of Wnt/b-catenin signaling in metastatic
outgrowth (Nguyen et al., 2009). Similarly, miR-335 specifically
suppresses breast cancer reinitiation at lung and bone metasta-
tic sites at least in part by inhibiting expression of the progenitor
cell transcription factor Sox4 (Png et al., 2012; Tavazoie et al.,
2008). In addition, expression of the NK2-related homeobox
transcription factor Nkx2-1 induces differentiation and thereby
restricts the metastatic ability of lung adenocarcinomas arising
in mice carrying conditional alleles of mutant Ras and p53 (Win-
slow et al., 2011).
In other cases, similar transcriptional mechanisms drive tumor
initiation and metastatic reactivation. For example, high-level
expression of the inhibitor of differentiation (Id) 1 and 3 transcrip-
tion factors is necessary to drive both tumor initiation at the
primary site and reinitiation at lung metastatic sites in TN breast
cancers (Gupta et al., 2007). CD24 controls both tumor initiation
and metastatic colonization through STAT3-mediated regulation
of NANOG in hepatocellular carcinoma (Lee et al., 2011). Finally,
coexpression of the mammary stem cell transcription factors
Slug and Sox9 promotes both the tumorigenic and metastasis-
seeding abilities of human breast cancer cells (Guo et al.,
2012). It appears that, although distinct contextual signals
govern the self-renewal of cancer stem cells during primary
tumor initiation and metastatic reactivation, these signals exert
their function by governing similar stemness-maintaining tran-
scriptional circuits (Figure 4).
Metastatic Niches, Stem Cell Signaling, and Metastatic
Reactivation
The ability of normal adult stem cells to balance self-renewal with
the production of differentiated progeny is governed by complex
adhesive and signaling interactions that occur within specialized
niches (Alvarez-Buylla and Lim, 2004; Hsu and Fuchs, 2012;
Morrison and Spradling, 2008). Recent studies suggest that
metastasis-initiating cells enter into dormancy and undergo re-
activation in response to niche signals, which are similar to those
that affect normal adult stem cells (Figure 5).
Some studies have suggested that carcinoma cells can estab-
lish a permissive niche in the target organ even prior to seeding.
In this model, primary tumors release systemic factors that upre-
gulate the production of fibronectin by fibroblasts residing in the
target organ, leading to the recruitment of VEGFR1+ hematopoi-
etic progenitor cells expressing the a4b1 fibronectin-binding
integrin. The hematopoietic cells in turn mold the local microen-
vironment within the premetastatic niche by secreting MMP-9
and other factors and promoting angiogenesis (Psaila and
Lyden, 2009). The relevance of these observations in dormancy
and reactivation has not been examined, but one envisions that
failure to establish a premetastatic niche may delay adaptation,
thereby favoring dormancy. In agreement with this hypothesis,
whereas adhesion to the abluminal surface of mature blood
vessels induces metastatic breast cancer cells to become
dormant, angiogenic sprouts create a local microenvironment
that facilitates reactivation (Ghajar et al., 2013).Recently, a gain-of-function cDNA screen in a mouse model
has revealed that Coco, the secreted antagonist of TGF-b li-
gands, induces solitary breast cancer cells to undergo reactiva-
tion at lungmetastatic sites (Gao et al., 2012b). Intriguingly, Coco
accumulates on the surface of metastasis-initiating cells and
shields them from the inhibitory action of lung-derived BMP pro-
teins (Figure 5). Coco is not required for colonization of bones
and brain because these organs contain sanctuaries devoid of
bioactive BMP. In a large cohort of patients, expression of a
14-gene Coco signature predicts relapse to the lung, but not to
the bone or brain, thus validating Coco as an organ-specific
reactivator (Gao et al., 2012b). These results suggest that metas-
tasis-initiating cells enter into dormancy in response to inhibitory
signals originating in the parenchyma of target organs. Similar to
adult stem cells establishing their niche, metastasis-initiating
cells have to overcome such inhibitory signals through produc-
tion of secreted antagonists (Wakefield and Hill, 2013). Coco
may be particularly effective among inhibitors because it has a
high affinity for BMP or because it binds to the pericellular matrix
and therefore reaches a high effective concentration at the cell
surface.
Additional stem cell signals participate in the reactivation of
micrometastatic lesions. The extracellular matrix protein tenas-
cin C, which is often found in stem cell niches, supports the
outgrowth of breast cancer micrometastases by elevating both
Notch and Wnt signaling (O’Connell et al., 2011; Oskarsson
et al., 2011). This latter effect may be attributed at least in part
to the ability of tenascin C to engage Syndecan 4, which has
been implicated as a coreceptor of theWnt receptor Fzd 7 (Bent-
zinger et al., 2013). Periostin, another matrix protein found in
stem cell niches, promotes micrometastatic outgrowth by facili-
tating the presentation of Wnt ligands to tumor cells (MalanchiCell 155, November 7, 2013 ª2013 Elsevier Inc. 757
Figure 6. Relationship between EMT, MET, and Metastatic Re-
activation
(Top) The existence of two types of metastatic cancer stem cells potentially
explains the relationship between MET and reactivation. Mesenchymal stem
cells are cycling slowly or are dormant, whereas E-cadherin-expressing can-
cer stem cells are proliferating vigorously, mirroring the behavior of normal
adult stem cells and transit-amplifying progenitors, respectively. Experiments
in mouse models suggest that, when metastasis is initiated by mesenchymal
cancer stem cells, an MET may be required for reactivation. If the mesen-
chymal stem cell is cycling slowly, it can give rise to its immediate progeny,
which expresses E-cadherin and proliferates rapidly, spurring metastatic
outgrowth. (Bottom) If the mesenchymal stem cell is dormant, it may have to
undergo a MET in order to become competent for reactivation.et al., 2012). While tenascin C is initially produced by the metas-
tasis-initiating cells and later by recruited stromal fibroblasts
(Oskarsson et al., 2011), periostin is secreted by stromal fibro-
blasts in response to TGF-b (Malanchi et al., 2012). Endothelial
tip cells within new vascular sprouts secrete both periostin and
TGF-b, boosting the availability of periostin in micrometastatic
lesions undergoing neoangiogenesis (Ghajar et al., 2013).
Intriguingly, in addition to coassembling with fibronectin and
modulating its adhesive and signaling capacity, tenascin C and
periostin can directly engage integrins (Midwood et al., 2004;
Nummela et al., 2012) (Figure 5). These considerations suggest
that the metastasis-initiating cells may induce formation of a
permissive niche consisting of matrix proteins specialized in
facilitating the activation of signaling pathways that activate their
self-renewal, such as Wnt and Notch.
Does Reversal of the EMT Precede or Follow
Reactivation?
Although pathological studies have suggested a role for the
reversal of the EMT, the mesenchymal-to-epithelial transforma-
tion (MET), in metastatic colonization, experimental proof has
remained scarce until recently (Chaffer et al., 2006; Korpal
et al., 2011). In addition, the ability of the EMT-inducing tran-
scription factors Twist, Snail, and Zeb to induce cancer stem
cell traits has led to the suggestion thatmetastasis-initiating cells
would exploit the enhanced self-renewal capacity conferred by
the EMT in order to undergo reactivation (Mani et al., 2008; Well-
ner et al., 2009). In this model, only the progeny of metastasis-
initiating cells would acquire epithelial features as a result of
aberrant differentiation.
Recent studies have provided mechanistic evidence for an
alternative scenario. Analysis of a chemical carcinogenesis
model of squamous carcinoma has revealed that, although
expression of Twist promotes tumor cell invasion and dissemina-
tion, inactivation of this factor is necessary to induce anMET and
to promote overt proliferation of micrometastatic lesions (Tsai
et al., 2012). In addition, the recently identified EMT inducer
Prrx-1 suppresses cancer stem cell properties instead of
inducing them, and it needs to be inactivated for successful colo-
nization of the lung by breast carcinoma cells (Ocan˜a et al.,
2012). In fact, suppression of Prrx-1 is sufficient to promote colo-
nization even in the presence of Twist or Snail, suggesting that
the effect of Prrx-1 is dominant. These results indicate that the
EMT can be uncoupled from the acquisition of stem cell poten-
tial. In the model that emerges from these data, metastasis-initi-
ating cells revert to an epithelial phenotype in order to outgrow
into macroscopic metastases. Stem cells, such as those of
Drosophila gonads, mouse intestinal epithelium, and skin hair
follicles, are connected to one another, to their immediate rapidly
proliferating progeny, and to supporting cells via E-cadherin-
dependent junctions (Hsu and Fuchs, 2012; Morrison and
Spradling, 2008). In addition to providing survival signals, such
junctions facilitate the transmission of contact-mediated (e.g.,
delta-Notch) and paracrine signals that regulate self-renewal
and differentiation (e.g.,Wnt). It is therefore possible that expres-
sion of E-cadherin enables metastasis-initiating cells to exploit
their proximity to one another and to their immediate progeny
to exchange signals that enhance their survival and proliferation.758 Cell 155, November 7, 2013 ª2013 Elsevier Inc.It remains to be addressed whether the acquisition of epithelial
features follows or precedes metastatic reactivation. Recent
studies have indicated that the abundance of circulating tumor
cells exhibiting mesenchymal traits correlates with disease
progression and metastasis in human breast cancer patients,
pointing to the existence of mesenchymal cancer stem cells
with metastatic capacity (Yu et al., 2013; Zhang et al., 2013). It
is possible that these cells possess high self-renewal capability
but cycle slowly in the parenchyma of the target organ, whereas
their immediate progeny expresses E-cadherin and proliferates
actively. Under this scenario, downregulation of the EMT-
inducing factor causes expansion of an E-cadherin-positive tran-
sient-amplifying compartment (Figure 6, top). Alternatively, the
mesenchymal cancer stem cells may be dormant and may
need to undergo a MET in order to be reactivated. In this latter
scenario, EMT-inducing factors may contribute to metastatic
dormancy (Figure 6, bottom). Future studies will be required to
distinguish between these two models.
Tumor Microenvironment and Micrometastatic
Reactivation
Like incipient primary tumors, micrometastatic outgrowths rely
on successful recruitment of endothelial cells, myeloid cells,
and stromal fibroblasts for their subsequent expansion, suggest-
ing that neoangiogenesis, inflammation, and fibrosis foster this
process (Joyce and Pollard, 2009). Recent studies indicate
that systemic and local signals govern these changes and that
a delay in their implementation may underlie micrometastatic
dormancy.
Systemic signals appear to promote dormancy of microme-
tastic lesions predominantly by blocking neoangiogenesis. The
prototypical endogenous inhibitors of angiogenesis, angiostatin
and endostatin, were isolated because of their ability to inhibit
the outgrowth of micrometastases upon secretion from primary
xenografts of lung carcinoma and hemangioendothelioma
(Hanahan and Folkman, 1996; Nyberg et al., 2005). Prosaposin,
secreted by prostate cancer cells, induces fibroblasts within
micrometastases to produce thrombospondin-1, thereby re-
straining neoangiogenesis and further expansion (Kang et al.,
2009). Conversely, positive systemic signals seem to induce
micrometastatic reactivation by creating a fibrotic stroma. Inoc-
ulation of two distinct cancer cell lines in separate mammary fat
pads, or in a mammary fat pad and intravenously to seed the
lung, has revealed that one tumor can function as an ‘‘instigator’’
and the other as a ‘‘responder.’’ In the absence of instigator, the
responder remains indolent, suggesting that systemic signals
can induce reactivation of dormant lesions. Intriguingly, the insti-
gator tumor was found to produce osteopontin, which activates
bone-marrow-derived hematopoietic progenitor cells. Upon
infiltrating the responder tumor, these cells produce granulin,
which induce activation of stromal cells and, hence, a desmo-
plastic reaction, i.e., the creation of a dense collagen-rich stroma
(Elkabets et al., 2011; McAllister et al., 2008). Furthermore,
extensively crosslinked collagen fibers, such as those created
by HIF1-induced lysil oxidase, can promote reactivation by
enhancing integrin-mediated conversion of mechanical forces
into biochemical signals (Barkan et al., 2010; Cox et al., 2013;
Levental et al., 2009; Samuel et al., 2011).
Locally derived signals that can act at multiple metastatic sites
include those acting on angiogenesis and inflammation. Produc-
tion of VEGF enables Lewis lung carcinoma micrometastic cells
to recruit Id1+ bone-marrow-derived endothelial cell progenitors
and to thereby trigger the angiogenic switch that is required for
their expansion (Gao et al., 2008). Angiopoietin 2 acts on TIE2-
expressing proangiogenic myeloid cells, promoting the conver-
sion of micrometastases into overt lesions in the MMTV-PyMT
mouse model of breast cancer (Mazzieri et al., 2011). In addition,
various microRNAs promote metastatic colonization in breast
cancer and melanoma by inducing recruitment of endothelial
cells and angiogenesis (Chou et al., 2013; Pencheva et al.,
2012; Png et al., 2012). Finally, the proteoglycan versican
engages Toll-like receptors on macrophages, inducing them to
secrete TNF-a and trigger an inflammatory cascade in Lewis
lung carcinoma micrometastases (Kim et al., 2009). The conse-
quences may be far reaching and include a MET that favors
outgrowth in the MMTV-PyMT mouse model of breast cancer
(Gao et al., 2012a).
In agreement with the notion that specific mechanisms pro-
mote colonization of the bone in multiple cancer types (Mundy,
2002), local signals act on osteoclasts to promote the activation
of dormant micrometastases in this organ. This phenomenon
has been best studied in breast cancer, where IL11 secreted
by cancer cells induce recruitment and activation of osteoclasts,
which in turn foster micrometastatic expansion (Kang et al.,
2003). NF-kB-mediated expression of VCAM1 enables recruit-
ment of monocytic precursors of osteoclasts, which express
the cognate receptor integrin a4b1, locally enhancing the gener-
ation of active osteoclasts within micrometastases (Lu et al.,
2011). Furthermore, the prometastatic cytokine TGF-b inducesexpression of Jagged by breast cancer cells, thereby activating
Notch signaling in bone-resident cells. As a consequence, oste-
oblasts release IL6, which stimulates tumor cell survival and
proliferation, and preosteoclasts are converted into osteoclasts,
setting in motion the vicious cycle of osteolysis (Sethi et al.,
2011).
While these observations suggest that systemic and local
factors can remodel the tumor microenvironment to foster
micrometastatic outgrowth, it is unclear to what extent and
under what circumstances a delay in the recruitment of a sup-
portive microenvironment underlies micrometastatic dormancy.
Toward a Unified Model of Metastatic Dormancy and
Reactivation
The evidence discussed above suggests that dormancy and
reactivation are governed by complex interactions between
metastasis-initiating cells and the microenvironment of the
target organ. Although direct, definitive evidence for the exis-
tence of metastatic stem cells is still lacking, the involvement
of specialized niches, stem cell signaling pathways, and stem
cell transcriptional circuits in metastatic colonization suggests
that the metastasis-initiating cells are cancer stem cells or
progenitors that revert to stem cell state upon infiltrating a
foreign microenvironment. Increasing evidence indicates that,
like normal adult stem cells, metastasis-initiating cells may enter
into dormancy in response to inhibitory niche signals (e.g., BMP)
or when deprived of activating niche signals (e.g., Wnt and
Notch). These considerations support the hypothesis that
metastasis-initiating cells mold a permissive niche or even
create an activating niche to support their expansion in a foreign
microenvironment (Sneddon andWerb, 2007). Differences in the
specific signaling circuits that govern the activation of cancer
stem cells from different tumor types as well as availability of
activating or inhibitory cues in the stroma of various target
organs may contribute to determine the organ specificity of
metastasis.
Therapeutic Implications
In spite of significant improvements in early diagnosis, many
cancer patients who have been treated with surgery eventually
develop distant metastases and succumb to the disease. The
efficacy of adjuvant therapy is predicated upon its ability to erad-
icate tumor cells that have undergone dissemination prior to
surgery. The realization that the tumor cells that are fated to
eventually outgrow into metastases are at least functionally
equivalent to cancer stem cells and experience a prolonged
period of dormancy suggest two distinct approaches to the pre-
vention of metastasis (Figure 7).
First, because dormant tumor cells are critically dependent on
signaling pathways that enhance their survival, interfering with
the operation of these pathways may improve the efficacy of
adjuvant therapy. Based on existing evidence, it would be infor-
mative to conduct preclinical studies in mouse models of
dormancywith inhibitors of Src, Akt, or TOR alone or in combina-
tion with chemotherapy or oncogene-targeted therapy.
Second, if the metastasis-initiating cells are or resemble can-
cer stem cells, they may be similarly refractory to chemotherapy
aswell as to targeted therapies.Whereas the first resistancemayCell 155, November 7, 2013 ª2013 Elsevier Inc. 759
Figure 7. Antimetastatic Therapies
Because dormant cancer cells are not cycling,
they may be relatively resistant to antimitotic
therapies. The studies discussed in this Review
suggest that dormant cancer cells may undergo
apoptosis in response to Src, PI-3K/TOR, or AKT
inhibitors. In addition, Notch and Wnt inhibitors or
BMP-R agonists may prevent the reactivation of
these cells. In contrast, adjuvant chemotherapies
and targeted therapies inhibit the survival and
proliferation of reactivated cancer cells, interfering
with the outgrowth of micrometastases.arise from upregulation of ABC cassette transporters, the
second suggests that these cells are sustained by signaling
pathways that are not directly downstream of prevalent onco-
genic mutations, such as the stem cell pathways. Therefore,
combination therapies that include agents targeting stem cells
pathways, such as Notch and Wnt, or reactivating BMP
signaling, as well as agents targeting canonical oncogenic path-
ways, may display efficacy in the adjuvant setting and in the
treatment of metastatic disease.
Finally, increased understanding of the mechanisms underly-
ing dormancy and reactivation may lead not only to the identifi-
cation of additional therapeutic targets, but also to changes in
the schedule of administration of adjuvant therapy. Dissemi-
nated tumor cells undergo reactivation over time in a seemingly
stochastic fashion. If this is the case, it may be more rational to
administer therapies that interfere with reactivation over short
periods of time distributed across several years.
Outlook
Dormancy and reactivation have now come into sharp focus as
integral components of tumor evolution. Although the studies I
have discussed indicate that the metastasis-initiating cells are
akin to cancer stem cells and that they enter into dormancy
and eventually undergo reactivation in response to niche signals
similar to those that regulate normal adult stem cells, several key
questions remain unresolved. Are the metastasis-initiating cells
the direct descendants of cancer stem cells, or do aberrantly
differentiated progenitors revert to a cancer stem cell state
upon infiltrating a target organ? Is the MET a prerequisite for
reactivation? Do metastases exhibit a hierarchical organization
similar to that proposed for primary tumors? What features
distinguish metastatic niches from normal stem cell niches?
Which signaling interactions and signaling pathways populate
the niches that the same type of tumor cells mold in different
target organs?When and where do cells endowed with metasta-
tic capacity accumulate the genetic or epigenetic changes that
enable reactivation?
Current approaches to study the molecular basis of metas-
tasis have been extremely successful, but they are not specif-
ically tailored to the study of dormancy and reactivation.
Answers to many of the above questions will require new
approaches. Lineage-tracing studies using newly developed
reporter systems, such as Confetti (Schepers et al., 2012), can
potentially offer insight into several outstanding issues in the760 Cell 155, November 7, 2013 ª2013 Elsevier Inc.area of dormancy and reactivation, especially if they are applied
to transgenic mouse models that faithfully mimic these pro-
cesses. In addition, a recently developed functional genetic
screen can lead to the rapid identification of strong mediators
of breast cancer reactivation in the lung (Gao et al., 2012a).
Future studies will be required to assess whether screening
shRNA libraries can lead to the identification of mediators of
dormancy and whether the strategy can be extended to other
target sites and tumor types. Ultimately, however, the results
will need to be validated by studying clinical samples. Improved
methods for genomic, phenotypic, and functional characteriza-
tion of circulating tumor cells and better access to samples of
metastases will be needed to accomplish this goal. Given the
current pace of discovery in the field of metastasis, it is likely
that these important questions will be addressed rapidly, open-
ing the way to the design and implementation of improved stra-
tegies for the treatment of cancer.
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